1. Home
  2. ATI vs ALNY Comparison

ATI vs ALNY Comparison

Compare ATI & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATI Inc.

ATI

ATI Inc.

SELL

Current Price

$171.61

Market Cap

21.4B

Sector

Industrials

ML Signal

SELL

Logo Alnylam Pharmaceuticals Inc.

ALNY

Alnylam Pharmaceuticals Inc.

SELL

Current Price

$156.79

Market Cap

21.6B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ATI
ALNY
Founded
1960
2002
Country
United States
United States
Employees
7600
115
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.4B
21.6B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
ATI
ALNY
Price
$171.61
$156.79
Analyst Decision
Strong Buy
Buy
Analyst Count
10
30
Target Price
$251.70
★ $299.96
AVG Volume (30 Days)
1.8M
★ 3.0M
Earning Date
10-29-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
11.76
★ 206.88
EPS
3.31
★ 18.42
Revenue
★ $4,043,500,000.00
$1,037,418,000.00
Revenue This Year
$15.08
$46.46
Revenue Next Year
$10.62
$19.78
P/E Ratio
$52.32
★ $8.67
Revenue Growth
N/A
★ 22.88
52 Week Low
$93.11
$149.18
52 Week High
$243.57
$479.79

Technical Indicators

Market Signals
Indicator
ATI
ALNY
Relative Strength Index (RSI) 44.31 30.51
Support Level $143.50 $149.18
Resistance Level $201.90 $237.47
Average True Range (ATR) 12.62 10.07
MACD 0.72 0.36
Stochastic Oscillator 38.80 14.18

Price Performance

Historical Comparison
ATI
ALNY

About ATI ATI Inc.

ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Share on Social Networks: